Asymptomatic Carotid Stenosis and Cognitive Improvement using Transcervical Stenting with Protective Flow Reversal Technique

ObjectivesThe relationship between carotid artery stenosis and cognitive function in individuals without a history of stroke is not clear. The possible pathomechanisms of cognitive impairment include silent embolization and hypoperfusion. In this study the aim was to assess cognitive changes after transcervical carotid artery stenting with proximal cerebral protection by flow reversal in patients with asymptomatic carotid stenosis, a novel technique that has been proved to decrease the number intraoperative emboli.Methods25 consecutive patients were assessed, of which 22 were men (88%) mean age of 74 years with severe asymptomatic carotid stenosis who underwent revascularization by carotid artery stenting (CAS) with flow reversal. Patients were evaluated 1 day before and 6 months after the procedure using a standardized neuropsychological battery. Test scores were adjusted according to age, sex, education level and were standardized (0–100). The mean of all the cognitive function scores yielded the global cognitive score (GCS).ResultsThere were no neurological complications during the procedure or during hospitalization in any patient. No deaths or cardiac complications occurred in any patient. The pre-procedure neuropsychological study showed cognitive impairment in: information processing speed in 15 patients (62.5%), visuospatial function in 14 (56.0%), memory in 18 (72.0%), executive functions in 14 (56.0%), language in three (12.0%), attention in 10 (40.0%), and global cognitive performance in eight (32.0%). Comparison of these scores with those obtained 6-month post-procedure showed significant improvement in GCS in all patients (p = .002), with a particularly marked gain in information processing speed (p = .018). Although significant improvement was not found for the remaining cognitive functions assessed, some gain was documented, and there was no deterioration.ConclusionsRevascularization by transcervical CAS with flow reversal for cerebral protection results in improved neurocognitive performance in asymptomatic elderly patients with severe carotid artery stenosis

Encefalopatía de Wernicke : descripción de 26 casos

La encefalopatía de Wernicke es una enfermedad por déficit de tiamina. Su causa más frecuente es el enolismo. La clínica típica es la tríada de trastornos de la motilidad ocular, ataxia y confusión mental. Objetivo: Descripción de los casos de encefalopatía de Wernicke diagnosticados en el Hospital General de Valencia entre los años 2000 y 2009. Resultados: De los 26 casos recogidos, el 88.46% presentaban como causa el enolismo. La tríada clásica se presentaba en menos del 50%, siendo el síntoma más frecuente la ataxia (80.76%). Las regiones más afectadas en RM eran el área periventricular y el tálamo.L'encefalopatia de Wernicke és una malaltia per dèficit de tiamina. La seva causa més freqüent és el enolisme. La clínica típica és la tríade de trastorns de la motilitat ocular, atàxia i confusió mental. Objectiu: Descripció dels casos d'encefalopatia de Wernicke diagnosticats en l'Hospital General de València entre els anys 2000 i 2009. Resultats: Dels 26 casos recollits, el 88.46% presentaven com causa el enolisme. La tríade clàssica es presentava en menys del 50%, sent el símptoma més freqüent l'atàxia (80.76%). Les regions més afectades en RM eren l'àrea periventricular i el tàlamo

GDAP1-related autosomal dominant Charcot-Marie-Tooth disease : phenotypical and MRI features

El present estudi es basa en la descripció de quatre famílies portadores d'una mateixa mutació puntual (p.R120W) en el gen GDAP1 que segreguen d'una manera autosòmica dominant. Les trobades més rellevants foren: - Els individus afectats varen tindre un començament més tardà i un fenotipus més lleu que les mutacions recessives del gen GDAP-1, però amb una gran variabilitat clínica. - La Resonància Magnètica Muscular va demostrar una afectació selectiva de la musculatura intrínseca del peu i la part distal del panxell. El compartiment posterior superficial de la musculatura del panxell estava més afectat que el compartiment anterolateral.The present study is based on the discovery of several families carrying a point mutation (p.R120W) in the GDAP1 gene segregating as an autosomal dominant trait. The main findings and results are as follows: - The affected individuals had a later disease onset and milder phenotypes than recessive GDAP-1 mutations, but with a great clinical variability. - Magnetic resonance imaging (MRI) revealed a selective involvement of intrinsic foot and distal calf muscles in all patients. The superficial compartment of the calf was consistently affected to a greater degree than the anterolateral one

L'ús dels biomarcadors plasmàtics (CKMB i BNP) facilita la detecció de patologies embòliques en l'ictus isquèmic agut

Per avaluar la utilitat dels biomarcadors en el diagnòstic etiològic de l'ictus agut, es van estudiar pacients amb ictus isquèmic agut no lacunar, en els quals es va fer una exploració cardiològica i es van determinar els biomarcadors plasmàtics seleccionats (CKMB, pèptid natriurètic cerebral(BNP), D-dímer, mioglobina i troponina I). Els pacients amb fibril·lació auricular i els pacients amb patologia embòlica en l'estudi amb ecocardiograma transtoràcic(ETT) van mostrar nivells més elevats de CKMB i BNP respecte els pacients amb ritme sinusal i estudi ETT normal, respectivament. Després de la regressió logística, CKMB i BNP es mantenien com a predictors independents de font embòlica

Urgències neurovasculars a l'hospital universitari Vall D'HEBRON (2001-2008)

La malaltia cerebrovascular és una de les patologies més prevalents a Catalunya, motivant un gran nombre de consultes a urgències i una de les primeres causes de mortalitat i discapacitat en adults. L'objectiu d'aquest estudi descriptiu fou explorar les característiques dels pacients amb patologia neurovascular atesos a urgències de l'Hospital Vall d'Hebron entre 2001 i 2008 a través de diverses variables. En vuit anys, s'ha produit un canvi en el perfil d'aquests pacients, amb l'augment de la complexitat diagnòstico-terapèutica de l'atenció de l'ictus a urgències. Amb tot, observem una disminució de la necessitat d'ingrés, la mortalitat i l'estada mitja hospitalària

Expert considerations and consensus for using dogs to detect human SARS-CoV-2-infections

Funding Information: This Open Access publication was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 491094227 “Open Access Publication Funding” and the University of Veterinary Medicine Hannover, Foundation.Peer reviewe

Estimates of costs for modelling return on investment from smoking cessation interventions

© 2018 The Authors. Background and aims: Modelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe-wide ROI model (EQUIPTMOD). Design: Focused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection. . Setting and participants: Adult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking related costs, child population (0-15 years) was also included. Measurements: Costs of treating smoking attributable diseases; productivity losses due to smoking attributable absenteeism; and costs of implementing smoking cessation interventions. . Findings: Annual costs (per case) of treating smoking attributable lung cancer were between €5,074 (Hungary) and €52,106 (Germany); coronary heart disease between €1,521 (Spain) and €3,955 (Netherlands); chronic obstructive pulmonary disease between €1,280 (England) and €4,199 (Spain); stroke between €1,829 (Hungary) and €14,880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25 (Hungary) and €220 (Germany). Costs (per recipient) of providing behavioral support were also wide-ranging: one-to-one behavioural support between €34 (Hungary) and €474 (Netherlands); and group-based behavioural support between €12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9 (Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain). Conclusions: Costs of treating smoking-attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions